JOP20200216A1 - تجارب للكشف عن التنكس العصبي - Google Patents
تجارب للكشف عن التنكس العصبيInfo
- Publication number
- JOP20200216A1 JOP20200216A1 JOP/2020/0216A JOP20200216A JOP20200216A1 JO P20200216 A1 JOP20200216 A1 JO P20200216A1 JO P20200216 A JOP20200216 A JO P20200216A JO P20200216 A1 JOP20200216 A1 JO P20200216A1
- Authority
- JO
- Jordan
- Prior art keywords
- methods
- assays
- antibodies
- neurodegeneration
- detect
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4005—Concentrating samples by transferring a selected component through a membrane
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N2030/022—Column chromatography characterised by the kind of separation mechanism
- G01N2030/027—Liquid chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
- G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2828—Prion diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
Abstract
تتوفر طرق لقياس كمية بروتين تاو الموجب تجاه p217 المعالَج بالفوسفور مرة واحدة أو مرات متعددة في عينة. وتتوفر أيضًا طرق للكشف عن اعتلالات تاو أو تشخيصها، وطرق لتحديد فاعلية علاج اعتلالات تاو، وطرق لتحديد ما إذا كان المريض (الكائن المشارك للدراسة) من الملائم علاجه بجسم مضاد لبروتين تاو الموجب تجاه p217 المضاد. ويصف الاختراع أيضًا أجسامًا مضادة لاستخدامها في الطرق والأدوات التي تشتمل على الأجسام المضادة.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862638524P | 2018-03-05 | 2018-03-05 | |
PCT/IB2019/051747 WO2019171258A1 (en) | 2018-03-05 | 2019-03-04 | Assays to detect neurodegeneration |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20200216A1 true JOP20200216A1 (ar) | 2020-09-03 |
Family
ID=67768541
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2020/0216A JOP20200216A1 (ar) | 2018-03-05 | 2019-03-04 | تجارب للكشف عن التنكس العصبي |
Country Status (16)
Country | Link |
---|---|
US (3) | US10591492B2 (ar) |
EP (1) | EP3762414A4 (ar) |
JP (2) | JP7399096B2 (ar) |
KR (1) | KR20200130354A (ar) |
CN (1) | CN112105640A (ar) |
AU (1) | AU2019232630A1 (ar) |
BR (1) | BR112020018193A2 (ar) |
CA (1) | CA3093198A1 (ar) |
EA (1) | EA202092087A1 (ar) |
IL (1) | IL277077A (ar) |
JO (1) | JOP20200216A1 (ar) |
MA (1) | MA53338A (ar) |
MX (1) | MX2020009278A (ar) |
PH (1) | PH12020551371A1 (ar) |
SG (1) | SG11202008574VA (ar) |
WO (1) | WO2019171258A1 (ar) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4040153A4 (en) * | 2019-09-30 | 2023-07-26 | Nipro Corporation | PROCEDURE FOR DETECTING TAU PROTEIN USING A BLOOD SAMPLE AS SAMPLE |
JP2023533806A (ja) * | 2020-07-14 | 2023-08-04 | ヤンセン ファーマシューティカ エヌ.ベー. | タウオパチー又はアミロイド形成疾患を検出するための血液ベースのアッセイ |
US20220127345A1 (en) * | 2020-10-26 | 2022-04-28 | Janssen Pharmaceutica Nv | Methods of Reducing Tau in Human Subjects |
BR112023014151A2 (pt) * | 2021-02-19 | 2023-10-10 | Eisai R&D Man Co Ltd | Anticorpo tau anti-pt217 |
CA3233533A1 (en) * | 2021-10-01 | 2023-04-06 | Todd Flower | Methods and devices for detecting cerebrospinal fluid leakage |
WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
CN114778856B (zh) * | 2022-05-30 | 2023-03-17 | 苏州宇测生物科技有限公司 | 磷酸化tau蛋白检测试剂盒 |
JP7450995B1 (ja) | 2023-04-13 | 2024-03-18 | 国立研究開発法人量子科学技術研究開発機構 | 被験者の脳のタウタンパク質の蓄積量を推定する方法及び装置 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
EP0600951A4 (en) | 1991-08-01 | 1996-10-30 | Paul H Voorheis | Diagnostic method for alzheimer's disease. |
EP0737208B1 (en) | 1993-12-21 | 2006-08-02 | Innogenetics N.V. | Monoclonal antibodies specific for phf-tau, hybridomas secreting them, antigen recognition by these antibodies and their applications |
JPH10506381A (ja) | 1994-07-29 | 1998-06-23 | イノジェネティックス・ナムローゼ・フェンノートシャップ | 特定のサブクラスまたは形態のホスホリレーションされたtauのエピトープに特異的なモノクローナル抗体、それらを分泌するハイブリドーマ、これらの抗体の抗原認識およびそれらの応用 |
EP1200073B1 (en) | 1999-07-06 | 2007-01-10 | Eli Lilly And Company | SELECTIVE iGluR 5? RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE |
DE60141752D1 (de) | 2000-06-30 | 2010-05-20 | Innogenetics Nv | Differentielle diagnose von neurologischen krankheiten |
US20030162230A1 (en) | 2000-09-27 | 2003-08-28 | Reagan Kevin J. | Method for quantifying phosphokinase activity on proteins |
JP4393382B2 (ja) | 2002-08-14 | 2010-01-06 | 三菱化学株式会社 | 中枢性タウ蛋白質特異的抗体 |
CA2765099A1 (en) | 2009-06-10 | 2010-12-16 | New York University | Phosphorylated tau peptide for use in the treatment of tauopathy |
JP6124591B2 (ja) | 2009-08-28 | 2017-05-10 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | タウオリゴマーに結合する抗体 |
GB201111361D0 (en) | 2011-07-04 | 2011-08-17 | Nordic Bioscience As | Biochemical markers for neurodegenerative conditions |
GB201112056D0 (en) * | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
MY186066A (en) * | 2011-12-20 | 2021-06-18 | Janssen Biotech Inc | Anti-phf-tau antibodies and their uses |
WO2014011972A1 (en) | 2012-07-13 | 2014-01-16 | Bristol-Myers Squibb Company | Tau immunoassay |
PT2935326T (pt) * | 2012-12-21 | 2020-09-14 | Biogen Ma Inc | Anticorpos anti-tau humanos |
JP2017512751A (ja) | 2014-02-14 | 2017-05-25 | アイピエリアン,インコーポレイティド | タウペプチド、抗タウ抗体、およびそれらの使用方法 |
EP3486256A3 (en) * | 2014-06-26 | 2019-08-28 | Janssen Vaccines & Prevention B.V. | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
TWI790642B (zh) * | 2015-06-05 | 2023-01-21 | 美商建南德克公司 | 抗-tau抗體及使用方法 |
US20180186855A1 (en) * | 2016-03-23 | 2018-07-05 | Alector Llc | Chimeric receptors and methods of use thereof |
PE20190208A1 (es) | 2016-05-02 | 2019-02-07 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau |
-
2019
- 2019-03-04 WO PCT/IB2019/051747 patent/WO2019171258A1/en unknown
- 2019-03-04 CA CA3093198A patent/CA3093198A1/en active Pending
- 2019-03-04 EA EA202092087A patent/EA202092087A1/ru unknown
- 2019-03-04 KR KR1020207028382A patent/KR20200130354A/ko not_active Application Discontinuation
- 2019-03-04 SG SG11202008574VA patent/SG11202008574VA/en unknown
- 2019-03-04 JP JP2020546103A patent/JP7399096B2/ja active Active
- 2019-03-04 AU AU2019232630A patent/AU2019232630A1/en active Pending
- 2019-03-04 US US16/291,264 patent/US10591492B2/en active Active
- 2019-03-04 EP EP19764468.5A patent/EP3762414A4/en active Pending
- 2019-03-04 MA MA053338A patent/MA53338A/fr unknown
- 2019-03-04 CN CN201980030651.6A patent/CN112105640A/zh active Pending
- 2019-03-04 JO JOP/2020/0216A patent/JOP20200216A1/ar unknown
- 2019-03-04 US US16/978,006 patent/US20200408781A1/en active Pending
- 2019-03-04 MX MX2020009278A patent/MX2020009278A/es unknown
- 2019-03-04 BR BR112020018193-5A patent/BR112020018193A2/pt unknown
-
2020
- 2020-01-24 US US16/751,886 patent/US10976325B2/en active Active
- 2020-09-01 IL IL277077A patent/IL277077A/en unknown
- 2020-09-02 PH PH12020551371A patent/PH12020551371A1/en unknown
-
2023
- 2023-12-05 JP JP2023205247A patent/JP2024037794A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
MA53338A (fr) | 2022-01-05 |
JP2021517239A (ja) | 2021-07-15 |
BR112020018193A2 (pt) | 2021-02-02 |
WO2019171258A1 (en) | 2019-09-12 |
CN112105640A (zh) | 2020-12-18 |
SG11202008574VA (en) | 2020-10-29 |
MX2020009278A (es) | 2021-01-08 |
KR20200130354A (ko) | 2020-11-18 |
US10976325B2 (en) | 2021-04-13 |
EA202092087A1 (ru) | 2020-11-17 |
JP7399096B2 (ja) | 2023-12-15 |
JP2024037794A (ja) | 2024-03-19 |
US20200182888A1 (en) | 2020-06-11 |
US20190271710A1 (en) | 2019-09-05 |
EP3762414A4 (en) | 2022-01-05 |
CA3093198A1 (en) | 2019-09-12 |
AU2019232630A1 (en) | 2020-09-24 |
EP3762414A1 (en) | 2021-01-13 |
PH12020551371A1 (en) | 2021-08-23 |
US20200408781A1 (en) | 2020-12-31 |
IL277077A (en) | 2020-10-29 |
US10591492B2 (en) | 2020-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020551371A1 (en) | Assays to detect neurodegeneration | |
SG10201906750XA (en) | Assays for detecting the presence or amount of an anti-drug antibody | |
EA201992748A1 (ru) | Диагностические анализы для обнаружения, количественного определения и/или отслеживания микроорганизмов и других аналитов | |
DE60300339D1 (de) | Verfahren zum Nachweis von Karzinomen in solubilisierten zervikalen Körperproben | |
BRPI0707645B8 (pt) | métodos in vitro para detecção de câncer em um indivíduo e para avaliação de prognóstico de um indivíduo tendo, ou suspeito de ter, câncer ovariano | |
MX2018009738A (es) | Anticuerpos monoclonales de proteína ns1 anti-virus del dengue. | |
BR112015021199A2 (pt) | método para determinar se uma infeção é bacteriana e/ou viral, dispositivo de fluxo lateral para detecção de um analito em uma amostra, e, dispositivo para detecção de um marcador bacteriano e/ou viral em uma amostra | |
WO2009092386A3 (en) | A new method to measure and characterize microvesicles in the human body fluids | |
BR112014006741A2 (pt) | método para monitorização, diagnóstico e/ou prognóstico de lesão renal aguda no estágio inicial | |
DE60129151D1 (de) | Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6) | |
BRPI0923199B8 (pt) | método para determinar a presença de anticorpos de fixação de complemento | |
BR112016007037A2 (pt) | método para detectar câncer pancreático, anticorpo monoclonal e kit | |
MX2019006098A (es) | Ensayo de anticuerpos. | |
FR2894675B1 (fr) | Distinction des meningites bacteriennes et virales | |
WO2012021741A3 (en) | Lateral flow assays for non-diagnostic analytes | |
WO2018172337A8 (en) | IMMUNOASSAY FOR THE DETECTION OF ZIKA VIRUS INFECTION | |
WO2014126487A3 (en) | Diagnosis and detection of dengue virus infection using chicken egg antibodies | |
MX2023007633A (es) | Inmunoensayo diva de la fiebre porcina africana. | |
DE602004026869D1 (de) | Diagnose von leberzirrhose mittels eines für menschliches protoonkogenes protein spezifischen antikörpers | |
NO20016080L (no) | Analyse | |
FR2874093B1 (fr) | Methode et trousse de determination du statut vaccinal de personnes | |
MX2017017100A (es) | Uso de la combinación de biomarcadores y anticuerpos séricos para el diagnóstico de tuberculosis humana. | |
Makiguchi et al. | A56 (PATHO)-PHYSIOLOGY OF THE ALVEOLUS: The Detection Of Cell Type-Specific Extracellular Vesicles Derived From Lung Epithelial Cells, Stable Or Cytokine-Activated Endothelial Cells By Exoscreen | |
GB0501564D0 (en) | Test for prion disease | |
UA131868U (uk) | Комплект для експрес-діагностики інфекційних захворювань |